Amlogenyx discloses $10 million raised in convertible note offering

Amlogenyx Inc., a Delaware corporation incorporated in 2023, filed a Form D with the Securities and Exchange Commission disclosing a securities offering with a first sale date of July 1, 2026. The company set a total offering amount of $20,000,000, of which $10,000,000 had been sold, leaving $10,000,000 remaining to be sold.¹

A total of two investors had already put money into the offering.¹ The securities offered consist of convertible promissory notes and equity securities issuable upon conversion of those notes.¹ The company set the minimum investment accepted from any outside investor at $0.¹

The filing states no sales commissions or finder's fees were paid. Both sales commissions and finders' fees were listed as $0.¹ The amount used for payments to executive officers, directors or promoters was also listed as $0.¹

The offering was claimed under the Rule 506(b) exemption.¹ The company indicated the offering is not being made in connection with a business combination transaction such as a merger, acquisition or exchange offer.¹ The company also stated it does not intend the offering to last more than one year.¹

Amlogenyx is based at 77 Digital Drive, Suite 200, in Novato, California.¹ The filing classifies the company's industry group as biotechnology within health care.¹ The Form D was signed by John Pinion, listed as the company's Chief Operating Officer, with a signing date of 2026-07-08.¹